Sign In
Buy ASMB
$24.57
+0.0800 (+0.327%)
At Close: Jun 03, 2026
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics t
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
08:05pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics ta
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatit
Assembly Biosciences GAAP EPS of -$3.00 misses by $0.90, revenue of $6.25M beats by $0.09M
11:06pm, Thursday, 10'th Mar 2022 Seeking Alpha
Assembly Biosciences press release (NASDAQ:ASMB): FY GAAP EPS of -$3.00 misses by $0.90.Revenue of $6.25M (-92.1% Y/Y) beats by $0.09M.
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
09:05pm, Thursday, 10'th Mar 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
01:00pm, Wednesday, 09'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will participate in a virtual fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 p.m. ET.
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
08:00am, Wednesday, 09'th Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Friday, 07'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
01:00pm, Thursday, 06'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
08:00am, Thursday, 06'th Jan 2022
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)
03:00pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)
11:36am, Tuesday, 07'th Dec 2021
Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Assembly Biosciences (NASDAQ:ASMB) Stock Rating Upgraded by Zacks Investment Research
06:46am, Tuesday, 07'th Dec 2021 Dakota Financial News
Zacks Investment Research upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a buy rating in a research report sent to investors on Friday morning, Zacks.com reports. The firm currently has $2.50 price objective on the biopharmaceutical companys stock. According to Zacks, Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for []
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Friday, 03'rd Dec 2021 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
-$0.48 Earnings Per Share Expected for Assembly Biosciences, Inc. (NASDAQ:ASMB) This Quarter
06:14am, Wednesday, 01'st Dec 2021 Transcript Daily
Brokerages expect Assembly Biosciences, Inc. (NASDAQ:ASMB) to announce earnings of ($0.48) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Assembly Biosciences earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.57). Assembly Biosciences reported earnings of ($1.11) per share in the same quarter last year, which []
